# European Patent Office

Type: organization

Source: GetYourBrief — https://getyourbrief.com/entity/european-patent-office
Canonical HTML page: https://getyourbrief.com/entity/european-patent-office

## Timeline

- **2026-Q3**: Bioequivalence Studies — Projected commencement of studies required for regional regulatory filings.
- **2026-03-17**: Strategic Agreement Signed — BioNxt announces a commercialization deal for Cladribine ODF in the Eurasian region.
- **2026-03-17**: Patent Grants Confirmed — Patents for the ODF formulation are officially granted in Europe and Eurasia.

## Recent coverage (7 stories, network-wide)

### Bio-Native AI Patent Could Accelerate Drug Discovery, HYFT Stock Rises 2.3%
2026-07-07 04:17:03 · Sector: health · Sentiment: Bullish · Impact: 7/10 · Sources: 3

MindWalk’s patent application on a biological data layer aims to give any AI model a contextual understanding of biology, promising to speed up drug target identification and clinical research. The move signals a shift toward data-centric healthcare AI.
Full story: https://gethealthbrief.com/story/hyft-patent-accelerate-drug-discovery-health-it

### HYFT Stock Jumps 2.3% on Patent to Own the Data Layer for AI Drug Discovery
2026-07-07 04:16:55 · Sector: bio · Sentiment: Bullish · Impact: 7/10 · Sources: 3

MindWalk’s European patent application for a high-dimensional biological data architecture could give it a proprietary platform for AI-native pharma R&D. The filing underscores a strategic pivot from model development to data infrastructure.
Full story: https://getbiobrief.com/story/mindwalk-biotech-data-layer-patent

### AI Commoditization Drives HYFT to Patent Data Layer; Shares Up 2.3%
2026-07-07 04:16:47 · Sector: ai · Sentiment: Bullish · Impact: 7/10 · Sources: 3

As AI models become interchangeable, MindWalk filed a European patent on the high-dimensional biological data layer beneath its platform, betting that durable value lies in context, not models. The filing highlights a strategic shift in AI infrastructure.
Full story: https://getaibrief.com/story/hyft-ai-data-layer-patent-strategy

### 3-Jurisdiction Patent Lock: WISe.ART’s Hardware NFT Patent Reshapes Art Law
2026-06-19 19:33:19 · Sector: legal · Sentiment: Bullish · Impact: 7/10 · Sources: 2

The European Patent Office’s grant to SEALSQ for ‘Back-to-Physical’ NFT technology introduces a legally enforceable, hardware-rooted method for proving artwork provenance. The patent, now spanning three jurisdictions, could shift the evidentiary burden in authenticity disputes and set new legal precedents for digital-physical asset linkage.
Full story: https://getlegalbrief.com/story/wiseart-patent-legal-art-authentication

### Quantum-Proof Chip NFT: WISe.ART Erases Art Fraud with Tamper-Proof Silicon
2026-06-19 19:33:13 · Sector: cyber · Sentiment: Bullish · Impact: 7/10 · Sources: 2

SEALSQ’s patented semiconductor-based NFT provisioning creates a hardware root of trust that is immune to software exploits, platform shutdowns, and future quantum attacks. WISe.ART’s platform becomes the first cybersecurity-hardened marketplace for physical artwork authentication.
Full story: https://getcyberbrief.com/story/wiseart-hardware-security-nft-art

### WISe.ART’s Back-to-Physical NFT Patent Bridges $60B Art Market with DeFi
2026-06-19 19:33:06 · Sector: crypto · Sentiment: Bullish · Impact: 7/10 · Sources: 2

The European patent for hardware-rooted NFTs enables verifiable on-chain provenance for physical artworks, a cornerstone for tokenizing real-world assets. WISe.ART’s platform could catalyze a new wave of liquid, tradeable art-backed tokens in the crypto economy.
Full story: https://getcryptobrief.com/story/wiseart-nft-physical-asset-tokenization

### BioNxt Secures Eurasian Commercialization Deal for Cladribine ODF
2026-03-17 08:34:27 · Sector: bio · Sentiment: Bullish · Impact: 6/10 · Sources: 2

BioNxt Solutions has entered a strategic partnership to commercialize its Cladribine Oral Dissolvable Film (ODF) across Eurasia, following successful patent approvals in both Europe and the Eurasian region. This move positions the company to capture market share in the Multiple Sclerosis (MS) treatment space with a novel, patient-friendly delivery mechanism.
Full story: https://getbiobrief.com/story/bionxt-cladribine-odf-eurasian-commercialization

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.